Pale Fire Capital SE bought a new stake in NGM Biopharmaceuticals, Inc. (NASDAQ:NGM – Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 33,800 shares of the company’s stock, valued at approximately $36,000. Several other hedge funds and […]
SOUTH SAN FRANCISCO, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering.
NGM Biopharmaceuticals (NASDAQ:NGM – Get Free Report) and NextCure (NASDAQ:NXTC – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, valuation, risk, analyst recommendations and earnings. Earnings & Valuation This table compares NGM Biopharmaceuticals […]
NGM Biopharmaceuticals (NASDAQ:NGM – Free Report) had its target price reduced by B. Riley from $7.00 to $3.50 in a research note issued to investors on Wednesday morning, Benzinga reports. They currently have a buy rating on the stock. NGM Biopharmaceuticals Price Performance NASDAQ:NGM opened at $0.76 on Wednesday. The firm has a market cap […]
NGM Biopharmaceuticals, Inc. (NASDAQ:NGM – Get Free Report) saw a large decrease in short interest in the month of August. As of August 31st, there was short interest totalling 2,520,000 shares, a decrease of 17.9% from the August 15th total of 3,070,000 shares. Approximately 5.7% of the shares of the stock are sold short. Based […]